Federal Register / Vol. 82, No. 171 / Wednesday, September 6, 2017 / Notices 42119 

5For the same reasons that led the Florida Board 

of Medicine to summarily suspend Registrant’s 

medical license, I find that the public interest 

necessitates that this Order be effective 

immediately. 21 CFR 1316.67. 

person licensed, registered or otherwise 

permitted, by . . . the jurisdiction in 

which he practices . . . to distribute, 

dispense, [or] administer . . . a 

controlled substance in the course of 

professional practice.’’ 21 U.S.C. 

802(21). Second, in setting the 

requirements for obtaining a 

practitioner’s registration, Congress 

directed that ‘‘[t]he Attorney General 

shall register practitioners . . . if the 

applicant is authorized to dispense . . . 

controlled substances under the laws of 

the State in which [s]he practices.’’ 21 

U.S.C. 823(f). Because Congress has 

clearly mandated that a practitioner 

possess state authority in order to be 

deemed a practitioner under the Act, 

DEA has held repeatedly that revocation 

of a practitioner’s registration is the 

appropriate sanction whenever he is no 

longer authorized to dispense controlled 

substances under the laws of the State 

in which he engages in professional 

practice. See, e.g., Calvin Ramsey, 76 FR 

20034, 20036 (2011); Sheran Arden 

Yeates, M.D., 71 FR 39130, 39131 

(2006); Dominick A. Ricci, 58 FR 51104, 

51105 (1993); Bobby Watts, 53 FR 

11919, 11920 (1988); Blanton, 43 FR 

27616 (1978). 

Moreover, because ‘‘the controlling 

question’’ in a proceeding brought 

under 21 U.S.C. 824(a)(3) is whether the 

holder of a practitioner’s registration ‘‘is 

currently authorized to handle 

controlled substances in the [S]tate,’’ 

Hooper, 76 FR at 71371 (quoting Anne 

Lazar Thorn, 62 FR 12847, 12848 

(1997)), the Agency has also long held 

that revocation is warranted even where 

a practitioner has lost his state authority 

by virtue of the State’s use of summary 

process and the State has yet to provide 

a hearing to challenge the suspension. 

Bourne Pharmacy, 72 FR 18273, 18274 

(2007); Wingfield Drugs, 52 FR 27070, 

27071 (1987). Thus, it is of no 

consequence that the Florida State 

Board of Medical Examiners has 

employed summary process in 

suspending Registrant’s state medical 

license. What is consequential is that 

Registrant is no longer currently 

authorized to dispense controlled 

substances in Florida, the State in 

which he is registered. I will therefore 

order that his registration be revoked. 

Order 

Pursuant to the authority vested in me 

by 21 U.S.C. 823(f) and 824(a), as well 

as 28 CFR 0.100(b), I order that DEA 

Certificate of Registration No. 

FA3645213, issued to Marcus W. 

Anderson, M.D., be, and it hereby is, 

revoked. I further order that any 

pending application of Marcus W. 

Anderson to renew or modify the above 

registration, or any pending application 

of Marcus W. Anderson for any other 

registration, be, and it hereby is, denied. 

This Order is effective immediately.5

Dated: August 28, 2017. 

Chuck Rosenberg, 

Acting Administrator. 

[FR Doc. 2017–18784 Filed 9–5–17; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Bulk Manufacturer of Controlled 

Substances Application: Stepan 

Company 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.33(a) on 

or before November 6, 2017. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.33(a), this is notice that on January 

20, 2017, Stepan Company, Natural 

Products Dept., 100 W. Hunter Avenue, 

Maywood, New Jersey 07607 applied to 

be registered as a bulk manufacturer of 

the following basic classes of controlled 

substances: 

Controlled substance Drug 

code Schedule 

Cocaine ................................... 9041 II 

Ecgonine ................................. 9180 II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

Dated: August 28, 2017. 

Demetra Ashley, 

Acting Assistant Administrator. 

[FR Doc. 2017–18789 Filed 9–5–17; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: KVK–Tech, Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.34(a) on 

or before October 6, 2017. Such persons 

may also file a written request for a 

hearing on the application pursuant to 

21 CFR 1301.43 on or before October 6, 

2017. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All request for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/LJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 


asabaliauskas on DSKBBXCHB2PROD with NOTICES
42120 Federal Register / Vol. 82, No. 171 / Wednesday, September 6, 2017 / Notices 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on July 18, 

2016, KVK–Tech, Inc., 110 Terry Drive, 

Newtown, Pennsylvania 18940 applied 

to be registered as an importer of 

Lisdexamfetamine (1205), a basic class 

of controlled substance listed in 

schedule II. 

The company plans to import the 

listed controlled substance in finished 

dosage form for clinical trials, research, 

and analytical purposes. Approval of 

permit applications will occur only 

when the registrant’s business activity is 

consistent with what is authorized 

under 21 U.S.C. 952(a)(2). Authorization 

will not extend to the import of FDA 

approved or non-approved finished 

dosage forms for commercial sale. 

Dated: August 28, 2017. 

Demetra Ashley, 

Acting Assistant Administrator. 

[FR Doc. 2017–18787 Filed 9–5–17; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Spex Certiprep Group, 

LLC 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.34(a) on 

or before October 6, 2017. Such persons 

may also file a written request for a 

hearing on the application pursuant to 

21 CFR 1301.43 on or before October 6, 

2017. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All request for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/LJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix of subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on October 

31, 2016, Spex Certiprep Group, LLC, 

203 Norcross Avenue, Metuchen, New 

Jersey 08840 applied to be registered as 

an importer of the following basic 

classes of controlled substances: 

Controlled substance Drug 

code Schedule 

Marihuana ............................... 7360 I 

Tetrahydrocannabinols ........... 7370 I 

The company plans to import the 

listed controlled substances for sale to 

research facilities for drug testing and 

analysis. 

In reference to drug codes 7360 

(marihuana) and 7370 (THC), the 

company plans to import a synthetic 

cannabidiol and a synthetic 

tetrahydrocannabinol. No other activity 

for these drug codes is authorized for 

this registration. 

Dated: August 28, 2017. 

Demetra Ashley, 

Acting Assistant Administrator. 

[FR Doc. 2017–18788 Filed 9–5–17; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Mylan Pharmaceuticals, 

Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.34(a) on 

or before October 6, 2017. Such persons 

may also file a written request for a 

hearing on the application pursuant to 

21 CFR 1301.43 on or before October 6, 

2017. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/LJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on 

December 9, 2016, Mylan 

Pharmaceuticals, Inc., 781 Chestnut 

Ridge Road, Morgantown, West Virginia 

26505 applied to be registered as an 

importer of the following basic classes 

of controlled substances: 

Controlled substance Drug 

code Schedule 

Amphetamine .......................... 1100 II 

Methylphenidate ...................... 1724 II 

Oxycodone .............................. 9143 II 

Hydromorphone ...................... 9150 II 

Methadone .............................. 9250 II 

Morphine ................................. 9300 II 

Fentanyl .................................. 9801 II 

The company plans to import the 

listed controlled substances in finished 

dosage form (FDF) from foreign sources 

for analytical testing and clinical trials 


asabaliauskas on DSKBBXCHB2PROD with NOTICES